This was attributed to the recognition of NPs by GLUT1 leading to enhanced cellular internalisation in glioma cells than in surrounding normal tissue and thus exhibiting promising in vivo anti-glioma activity [54]. The gene discussed is SLC2A1; the disease is central nervous system cancer.